Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
73,167,927
-
Share change
-
-27,186,793
-
Total reported value
-
$90,726,991
-
Put/Call ratio
-
2.4%
-
Price per share
-
$1.24
-
Number of holders
-
114
-
Value change
-
-$25,689,277
-
Number of buys
-
40
-
Number of sells
-
81
Institutional Holders of ZIOPHARM ONCOLOGY INC - COM (TCRT) as of Q2 2022
As of 30 Jun 2022,
ZIOPHARM ONCOLOGY INC - COM (TCRT) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
73,167,927 shares.
The largest 10 holders included
MSD Partners, L.P., DISCOVERY CAPITAL MANAGEMENT, LLC / CT, VANGUARD GROUP INC, BlackRock Inc., Laurion Capital Management LP, JPMORGAN CHASE & CO, MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, TWO SIGMA ADVISERS, LP, and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
114
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.